Rockwell Medical, Inc. SEC filings RMTI
Rockwell Medical, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Oct 29, 2009. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (material agreement, unregistered share sale, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | May 11, 2026 | — |
| DEF 14A | Proxy statement | Apr 30, 2026 | Apr 30, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 20, 2026 | Apr 20, 2026 |
| DEF 14A | Proxy statement | Apr 14, 2025 | May 20, 2025 |
| DEF 14A | Proxy statement | Apr 15, 2024 | May 21, 2024 |
| DEF 14A | Proxy statement | Apr 17, 2023 | May 23, 2023 |
| DEF 14A | Proxy statement | Apr 8, 2022 | May 9, 2022 |
| PRE 14A | Preliminary proxy statement | Mar 21, 2022 | May 9, 2022 |
| DEF 14A | Proxy statement | Apr 30, 2021 | Jun 17, 2021 |
| DEFA14A | Additional proxy material | May 7, 2020 | — |
| DEF 14A | Proxy statement | Apr 20, 2020 | May 18, 2020 |
| DEFA14A | Additional proxy material | Jun 10, 2019 | — |
| DEFA14A | Additional proxy material | Jun 7, 2019 | — |
| DEFA14A | Additional proxy material | May 21, 2019 | — |
| DEF 14A | Proxy statement | Apr 30, 2019 | Jun 6, 2019 |
| PRE 14A | Preliminary proxy statement | Apr 12, 2019 | Jun 6, 2019 |
| DEFA14A | Additional proxy material | Jun 21, 2018 | — |
| DEFA14A | Additional proxy material | Jun 12, 2018 | — |
| DEFA14A | Additional proxy material | Jun 7, 2018 | — |
| DEF 14A | Proxy statement | Apr 30, 2018 | Jun 21, 2018 |
| PRE 14A | Preliminary proxy statement | Apr 13, 2018 | Jun 21, 2018 |
| DEFA14A | Additional proxy material | May 26, 2017 | — |
| DEFA14A | Additional proxy material | May 22, 2017 | — |
| DEFA14A | Additional proxy material | May 22, 2017 | — |
| DEFA14A | Additional proxy material | May 18, 2017 | — |
| DEFA14A | Additional proxy material | May 16, 2017 | — |
| DEFA14A | Additional proxy material | May 11, 2017 | — |
| DEFA14A | Additional proxy material | May 10, 2017 | — |
| DEFA14A | Additional proxy material | May 10, 2017 | — |
| DEFA14A | Additional proxy material | May 10, 2017 | — |
| DEFA14A | Additional proxy material | May 9, 2017 | — |
| DEFA14A | Additional proxy material | May 9, 2017 | — |
| DEFA14A | Additional proxy material | May 4, 2017 | — |
| DEFA14A | Additional proxy material | Apr 24, 2017 | — |
| DEFA14A | Additional proxy material | Apr 21, 2017 | — |
| DEFA14A | Additional proxy material | Apr 4, 2017 | — |
| DEFA14A | Additional proxy material | Mar 3, 2017 | — |
| DEFA14A | Additional proxy material | May 31, 2016 | — |
| DEF 14A | Proxy statement | Apr 18, 2016 | Jun 2, 2016 |
| DEF 14A | Proxy statement | Apr 13, 2015 | May 21, 2015 |
| DEF 14A | Proxy statement | Apr 14, 2014 | May 22, 2014 |
| DEF 14A | Proxy statement | Mar 29, 2013 | Apr 30, 2013 |
| PRE 14A | Preliminary proxy statement | Mar 19, 2013 | Apr 30, 2013 |
| DEF 14A | Proxy statement | Apr 13, 2012 | May 24, 2012 |
| PRE 14A | Preliminary proxy statement | Mar 23, 2012 | Mar 24, 2012 |
| DEF 14A | Proxy statement | Apr 15, 2011 | May 26, 2011 |
| DEF 14A | Proxy statement | Apr 15, 2010 | May 27, 2010 |
Showing 47 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RMTI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wixom, MI
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1041024
- Former names
- ROCKWELL MEDICAL TECHNOLOGIES INC (until Jun 14, 2012)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.